* Q2 EPS beats estimates by $1
* Eylea is U.S. market leader in all indications - conf call
* Dupixent rakes in $29 million, Kevzara generates $1 mln (Adds conference call details; updates shares)
Aug 3 (Reuters) - Regeneron Pharmaceuticals Inc's quarterly profit handsomely beat estimates on strong demand for its flagship Eylea drug, prompting the U.S. drugmaker to raise its full-year growth forecast for the eye treatment.
Sales of Eylea, which is used to treat macular degeneration and other eye disorders that cause age-related vision loss, came in at $919 million and beat analysts' estimates, helped by higher demand as the U.S. population ages.
Eylea had maintained a market-leading position in all approved indications in the United States, despite competition from rival drugs such as Roche Holding AG and Novartis AG's Lucentis, Regeneron said in a post-earnings call.
Eylea has powered much of Regeneron's explosive growth since 2011, and accounted for nearly 60 percent of quarterly sales.
The company now expects U.S. Eylea sales to grow 10 percent over 2016. It had previously estimated single-digit percentage growth over the $3.32 billion generated in U.S. sales last year.
The U.S. biotech is betting on two recently approved, potential blockbusters - its eczema treatment Dupixent and rheumatoid arthritis drug Kevzara - to reduce its heavy reliance on Eylea.
Partner Sanofi revealed earlier this week that Dupixent generated sales of 26 million euros ($30.88 million) in the drug's first full quarter on the market. This came in well short of analysts' expectations.
"Given the weakness in Regeneron over the last few days with the disappointing initial Dupixent number, the solid Eylea beat should improve perception," Morgan Stanley analysts wrote in a note.
Regeneron on Thursday said it was encouraged by initial Dupixent adoption, and expected to secure broad U.S. market access and European approval by the end of 2017.
Key data from a trial testing Dupixent as a treatment for asthma is also expected later this year.
Kevzara, which was launched in the United States in late May, generated $1 million in sales.
Regeneron is also banking on a plethora of experimental drugs in its pipeline to fuel long-term growth. In particular, it highlighted the potential of its cancer immunotherapy, REGN2810.
Lower expenses and a significantly smaller tax rate also helped Regeneron smash analysts' estimates for adjusted profit by a dollar, according to Thomson Reuters I/B/E/S.
Total revenue of $1.47 billion also beat estimates.
The company's stock was little changed in Thursday morning trading. ($1 = 0.8421 euros) (Reporting by Manas Mishra and Natalie Grover in Bengaluru; Editing by Arun Koyyur and Supriya Kurane)